Skip to content

Zhengyuan Capsule Treating Cancer Related Fatigue

Efficacy of Zhengyuan Capsule in the Treatment of Cancer Related Fatigue after Lung Cancer Surgery: a Randomized, Double-blind, Placebo-controlled, Single-center Clinical Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022712
Enrollment
Unknown
Registered
2019-04-23
Start date
2019-05-10
Completion date
Unknown
Last updated
2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer related fatigue

Interventions

treatment group:Zhengyuan capsule
control group:placebo

Sponsors

Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Histologically or cytologically confirmed lung cancer; 2.Clinical confirmed cancer related fatigue,and Chinese version of Cancer Fatigue Scale(CFS) score of=40 and 18 and =75 years, male or female; 4.With Stage I lung cancer, status-post surgery with R0-resection between 3 weeks and 1 month,and chemoradiotherapy is not required; 5.The Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of =2 points ; 6.Life expectancy = 6 months; 7.Informed consent form signed voluntarily.

Exclusion criteria

Exclusion criteria: 1. Pregnant, breastfeeding or plan to pregnant; 2. Allergic constitution or allergic to the ingredients of this preparation; 3. Cognitive impairments or verbal expression defects, which are difficult to cooperate with the investigator; 4. Suspected or confirmed drug abuse or alcoholism; 5. Combined severe cardiovascular, digestive, renal, endocrine, hematopoietic, neurological or chronic disease, which may affect effect judgment; 6. Abnormal liver function (ALT or AST=2 times Upper limits of normal); abnormal renal function (serum creatinine level is above upper limits of normal); 7. Participated in other clinical trials within three months; 8. The investigators considered that inappropriate for inclusion.

Design outcomes

Primary

MeasureTime frame
CFS score;

Countries

China

Contacts

Public ContactMing Zhang

Shanghai Chest Hospital

gason2000@126.com+86 18017320233

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026